SCHEDULE: Millennium Management Discloses NeoGenomics Stake

Millennium Management LLC and affiliates reported beneficial ownership of 4.97% of NeoGenomics, Inc. common stock, having previously exceeded 5%.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported their beneficial ownership of NeoGenomics, Inc. common stock.
• They collectively beneficially owned 6,436,776 shares of NeoGenomics, Inc. common stock.
• This represents 4.97% of the class.
• The reporting persons acquired beneficial ownership of more than 5% on November 24, 2025, but ceased to be beneficial owners of more than 5% by the date of this filing.
• The reporting persons filed under Rule 13d-1(b), indicating no intent to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as it is a factual disclosure of beneficial ownership. The reduction below 5% by the filing date could be seen as slightly negative, but the filing itself is purely informational.

Positives

• Initial acquisition of a stake exceeding 5% by a prominent institutional investor like Millennium Management could signal confidence in NeoGenomics, Inc. at the time of the event.

Negatives

• The reporting persons ceased to be beneficial owners of more than 5% of the outstanding common stock by the filing date, indicating a reduction in their stake below the reporting threshold.

Risks

• A reduction in a significant institutional holding could be interpreted by the market as a diminished investment thesis or a re-evaluation of the company's prospects, potentially leading to negative market sentiment or stock price volatility.

Future Outlook

No forward-looking statements or guidance regarding NeoGenomics, Inc.'s future performance or operations are provided.

Management Comments

• Certifications from Gil Raviv, Global General Counsel for Millennium Management LLC and Millennium Group Management LLC, and Israel A. Englander, state that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Industry Context

This disclosure reflects a standard regulatory requirement for institutional investors holding significant stakes. The reduction of the stake below 5% by the filing date is a notable event in the context of institutional investment trends within the diagnostics and oncology sector, where NeoGenomics operates.

Comparison to Industry Standards

• Not applicable, as this filing is a disclosure of beneficial ownership and does not contain operational or financial results for comparison.

Stakeholder Impact

• Shareholders may note the change in a significant institutional investor's position, which could influence market perception and trading activity.

Next Steps

• No future actions, events, or milestones for NeoGenomics, Inc. or the reporting persons are specified beyond the regulatory disclosure.

Key Dates

Keywords

NeoGenomics Inc, Millennium Management LLC, Israel A. Englander, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake